Two Sigma Advisers
BIOL

Two Sigma Advisers’s Biolase, Inc. BIOL Stock Holding History

Two Sigma Advisers’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-155
Closed -$248K – 2845
2021
Q3 		$248K Buy
155
+134
+638% +$219K ﹤0.01% 2181
2021
Q2 		$36K Buy
+21
New +$39K ﹤0.01% 2392

Other funds holding BIOL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Advisers's BIOL Position: Q4 2021 in Review

Two Sigma Advisers sold out of Biolase, Inc. (BIOL) in Q4 2021, closing a stake of 155 shares — an estimated $248K sold.

Two Sigma Advisers first reported a position in BIOL in Q2 2021 and held it in 2 quarters. The position peaked at $248K in Q3 2021. 38 funds tracked by Wall St. Rank hold BIOL as of Q4 2021.

  • Two Sigma Advisers reported no remaining Biolase, Inc. position as of Q4 2021 after selling out during the quarter.
  • Two Sigma Advisers sold 155 Biolase, Inc. shares in Q4 2021, an estimated $248K.
  • Two Sigma Advisers first reported a position in Biolase, Inc. in Q2 2021 and held it in 2 quarters.
  • Two Sigma Advisers's Biolase, Inc. position peaked at $248K in Q3 2021.
  • 38 funds tracked by Wall St. Rank held Biolase, Inc. as of Q4 2021.

Based on Two Sigma Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.